Special Issue

Advances in Vaccines against Infectious Diseases

Message from the Guest Editor

The occurrence of infectious diseases still has a significant impact on public health and the economy. Infectious diseases spread from person to person, and it is important to control the spread of these diseases globally to ensure the well-being of everyone and a country's economic prosperity. Vaccination is an important step towards achieving universal health coverage. Recent outbreaks of emerging, re-emerging, and neglected infectious diseases show the need for effective control and prevention measures, including advancements in vaccine development, adjuvants, and immunity studies to understand the protective effects of the vaccines better. This Special Issue invites researchers to contribute their insights and on vaccines and vaccination, exploring vaccines and emerging, reemerging, and neglected infectious diseases. Original articles, perspectives, and reviews on vaccine studies. viral immunology, and vaccine tools that facilitate examining these interactions at an immunological molecular level are welcome.

Guest Editor

Dr. Salvatore Giovanni De Simone

Center for Technological Development in Health (CDTS), National Institute of Science and Technology for Innovation in Neglected Diseases Populations (INCT-IDPN), Oswaldo Cruz Foundation (FIOCRUZ), Rio de Janeiro 21040-900, RJ, Brazil

Deadline for manuscript submissions

31 December 2024



an Open Access Journal by MDPI

Impact Factor 5.2 CiteScore 8.9 Indexed in PubMed



mdpi.com/si/193156

Vaccines
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

mdpi.com/journal/vaccines





an Open Access Journal by MDPI

Impact Factor 5.2 CiteScore 8.9 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17.6 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2024).

